583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians

Abstract Background Peru started its national vaccination campaign in February 2021 using Sinopharm vaccine, targeting healthcare personnel on its initial phase. Although the immunogenicity of this vaccine was tested in clinical trials, there are no studies that evaluated the humoral response post v...

Descripción completa

Guardado en:
Autores principales: María Victoria Lopera, Romina Vera, Carlos Tapia, Carlos Cabrera, Jose Armando Gonzales Zamora, Jorge Alave
Formato: Artículo
Lenguaje:inglés
Publicado: 2021
Materias:
Medicine
Immunogenicity
Vaccination
Antibody
Titer
Cohort
Neutralizing antibody
Antibody titer
Immunology
Coronavirus disease 2019 (COVID-19)
Internal medicine
Virology
Disease
Infectious disease (medical specialty)
Health Sciences Medicine Infectious Diseases SARS-CoV-2 and COVID-19 Research
Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Biology vaccines and immunoinformatics approaches
Health Sciences Medicine Infectious Diseases COVID-19 Clinical Research Studies
Acceso en línea:Descargar el archivo
Enlace permanente (DOI o Handle)
Enlace permanente (DOI o Handle)
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares: 583. <i>SARS-CoV-2</i> Spike Protein S1/S2 Antibodies after Vaccination with Sinopharm in Peruvian Physicians

Ejemplares similares